---
title: "AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299045372.md"
description: "CNBC traders highlighted AstraZeneca, Leidos, Expeditors International, and US 10-year Treasuries on 'Final Trades'. Strong Q2 earnings drove gains for Leidos and Expeditors, both beating analyst estimates. AstraZeneca saw regulatory approval for a breast cancer treatment and merger speculation with Bristol Myers Squibb. Liz Thomas recommended the 10-year Treasury. Shares of AstraZeneca, Leidos, and Expeditors all rose following their respective reports."
datetime: "2026-09-15T11:39:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299045372.md)
  - [en](https://longbridge.com/en/news/299045372.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299045372.md)
generator: "portal-rs"
---

# AstraZeneca, Leidos, Expeditors International And More On CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” **Jim Lebenthal**, partner and chief market strategist at Cerity Partners, picked **AstraZeneca PLC** (NYSE:AZN),

Last week, Cambridge, U.K.-based AstraZeneca secured regulatory approval for a new breast cancer treatment while reporting strong Phase 3 trial data for its lung cancer and respiratory therapies.

In August, the Financial Times reported that **Bristol Myers Squibb** (NYSE:BMY) and AstraZeneca were considering a nearly $400 million merger.

***Don’t forget to check out our premarket coverage here***.

**Stephen Weiss**, chief investment officer and managing partner of Short Hills Capital Partners, named **Leidos Holdings, Inc.** (NYSE:LDOS) as his final trade.

Supporting his choice, Leidos reported better-than-expected second-quarter financial results on Aug. 4 and raised its FY26 guidance. Leidos reported quarterly earnings of $3.26 per share, which beat the analyst consensus estimate of $2.91 per share. The company reported quarterly sales of $4.558 billion, which beat the analyst consensus estimate of $4.437 billion.

**Liz Thomas**, SoFi head of investment strategy, recommended **US 10-year Treasury**.

**Joseph M. Terranova**, senior managing director for Virtus Investment Partners, picked **Expeditors International of Washington, Inc.** (NYSE:EXPD).

On the earnings front, Expeditors Intl, on Aug. 4, posted better-than-expected second-quarter earnings. The company reported quarterly earnings of $2.03 per share, beating the analyst consensus estimate of $1.67 per share. The company reported quarterly sales of $3.502 billion, which beat the analyst consensus estimate of $2.888 billion.

## **Price Action**

-   AstraZeneca shares gained 2.3% to close at $163.78 on Monday.
-   Leidos shares gained 3.1% to close at $132.83.
-   Expeditors International shares rose 0.5% to close at $193.61 on Monday.

 **See More: Top Value Stocks** 

*Photo via Shutterstock*

### Related Stocks

- [EXPD.US](https://longbridge.com/en/quote/EXPD.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BMY.US](https://longbridge.com/en/quote/BMY.US.md)
- [LDOS.US](https://longbridge.com/en/quote/LDOS.US.md)
- [SOFI.US](https://longbridge.com/en/quote/SOFI.US.md)
- [VRTS.US](https://longbridge.com/en/quote/VRTS.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [Leidos Finalizes Amended JV Agreement With AHP, Granting AHP Board Control and 7-Year Exit Right](https://longbridge.com/en/news/300931731.md)
- [Leidos Security Enterprise Solutions and Analogic close deal to strengthen global security screening capabilities | LDOS Stock News](https://longbridge.com/en/news/300930827.md)
- [Why Is Bristol-Myers Squibb (BMY) In Focus After New Phase 3 Myeloma Data?](https://longbridge.com/en/news/300448973.md)
- [AstraZeneca opens new R&D centre in Cambridge, US](https://longbridge.com/en/news/301014813.md)
- [Bristol Myers Squibb secures expanded US approval for Camzyos](https://longbridge.com/en/news/300671144.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**